Home
Reels
Groups
Pages
See More
Groups Pages Events Blogs Funding
Sign In Sign Up
Night Mode
Autologous vs. Allogeneic: The CAR T Manufacturing Race
The promise of CAR T therapy is constrained by a manufacturing challenge: creating personalized treatments at scale is complex, time-consuming, and expensive. Autologous therapy—using the patient's own cells—requires a bespoke manufacturing process for each patient, with vein-to-vein times that can delay treatment. Allogeneic therapy—using donor cells—offers the...
0 Comments ·0 Shares ·21 Views ·0 Reviews
Please log in to like, share and comment!